- Home
- WLGS vs SBFM Comparison
WLGS vs SBFM Comparison
Compare WLGS & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WLGS
- SBFM
- Stock Information
- Founded
- WLGS 1981
- SBFM 2006
- Country
- WLGS Hong Kong
- SBFM United States
- Employees
- WLGS N/A
- SBFM N/A
- Industry
- WLGS Engineering & Construction
- SBFM Biotechnology: Pharmaceutical Preparations
- Sector
- WLGS Consumer Discretionary
- SBFM Health Care
- Exchange
- WLGS Nasdaq
- SBFM Nasdaq
- Market Cap
- WLGS 22.2M
- SBFM 3.7M
- IPO Year
- WLGS 2023
- SBFM N/A
- Fundamental
- Price
- WLGS $2.58
- SBFM $3.14
- Analyst Decision
- WLGS
- SBFM
- Analyst Count
- WLGS 0
- SBFM 0
- Target Price
- WLGS N/A
- SBFM N/A
- AVG Volume (30 Days)
- WLGS 269.6K
- SBFM 90.8K
- Earning Date
- WLGS 11-14-2024
- SBFM 11-11-2024
- Dividend Yield
- WLGS N/A
- SBFM N/A
- EPS Growth
- WLGS N/A
- SBFM N/A
- EPS
- WLGS N/A
- SBFM N/A
- Revenue
- WLGS $6,825,879.00
- SBFM $30,481,982.00
- Revenue This Year
- WLGS N/A
- SBFM $86.70
- Revenue Next Year
- WLGS N/A
- SBFM $126.76
- P/E Ratio
- WLGS N/A
- SBFM N/A
- Revenue Growth
- WLGS 63.69
- SBFM 109.82
- 52 Week Low
- WLGS $0.40
- SBFM $2.42
- 52 Week High
- WLGS $4.20
- SBFM $660.00
- Technical
- Relative Strength Index (RSI)
- WLGS 58.66
- SBFM 52.62
- Support Level
- WLGS $2.33
- SBFM $2.85
- Resistance Level
- WLGS $4.20
- SBFM $3.05
- Average True Range (ATR)
- WLGS 0.65
- SBFM 0.14
- MACD
- WLGS 0.04
- SBFM 0.03
- Stochastic Oscillator
- WLGS 34.29
- SBFM 85.29
About WLGS Wang & Lee Group Inc.
WANG & LEE Group Inc operates as an investment holding company. The firm conducts its primary operations through its indirectly wholly owned subsidiary WANG and LEE CONTRACTING LIMITED (WLHK). WLHK provides contract engineering, installation, and out-fitting of the following products and services: low voltage (220v/phase 1 or 380v/phase 3) electrical systems, mechanical ventilation and air-conditioning systems (MVAC), fire safety systems, and water supply and sewage disposal systems.
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. The company is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA targeted for liver cancer, (ii) SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections, and (iii) Adva-27a for pancreatic cancer. The company has two reportable segments: Prescription Generic Pharmaceuticals ("Generic Pharmaceuticals") and Nonprescription Over-The-Counter Products ("OTC Products"). The company generates the majority of its revenue from the Generic Pharmaceuticals segment.